GLPwatch
Distinguishing among incretin-based therapies. Introduction.
J Fam Pract · 2010
Last updated 2026-05-28A survey found that people are unsure about how GLP-1 drugs differ from DPP-4 drugs, which both help control blood sugar. Both types of drugs are generally effective and safe, but the abstract does not provide specific details about their differences or how they work.
AI summary of the abstract below.
| Journal | J Fam Pract, 2010 |
|---|---|
| Citations | 1 |
| Relative citation ratio | 0.08 |
| NIH percentile | 6 |
| Molecules | — |
Abstract
The "treat to target" approach is to quickly achieve the target glycosylated hemoglobin (AIC) goal of <7% in most people, and then intensify or change therapy as needed to maintain glycemic control. Results of an online survey demonstrate uncertainty regarding the clinical differences between glucagon-like peptide (GLP-1) agonists and dipeptidyl peptidase (DPP)-4 inhibitors. The increasingly important roles of the GLP-1 agonists and DPP-4 inhibitors stem from their overall good efficacy and safety profiles compared with other treatment options.
Verbatim abstract via PubMed 20824238 ↗